Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats

Journal of Surgical Research

Volumn 63, Issue 1, 1996, Pages 143-146

  Schmidt, Hans ^a   Rush, Benjamin ^a   Simonian, Gregory ^a   Murphy, Thomas ^a   Hsieh, John ^a   Condon, Michael ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CANNULATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMORAL ARTERY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEDATION; SEPSIS; VERTIGO;

EID: 0029902732     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0237     Document Type: Conference Paper

References (20)

1. Rangel-Frausto, M. S., Pittet, D., Costigan, M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 273: 117-123, 1995.
2. Ziegler, E. J., Fisher, C. J., Sprung, C. L., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New Engl. J. Med. 324: 429-436, 1991.
3. Greenman, R. L., Schein, R. M., Martin, M. A., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102, 1991.
4. Mellin, G. W., and Katzenstein, M. The saga of thalidomide. New Engl. J. Med. 267: 1184-1193, 1962.
5. Sampaio, E. P., Kaplan, G., Miranda, A., et al. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J. Infect. Dis. 168: 408-14, 1993.
6. Moreira, A. C., Sampaio, E. P., Zmuidzinas, A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRna degradation. J. Exp. Med. 177: 1675-80, 1993.
7. Vogelsang, G. B., Farmer, E. R., Hess, A. D., et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl. J. Med. 326: 1055-1058, 1992.
8. Makonkawkeyoon, S., Limson-Pobre, R. N. R., Moreira, A. L., et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 90: 5974-5978, 1993.
9. Eriksson, T., Bjorkman, S., and Fyge, A. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: Avoiding hydrolytic degradation. J. Chromatogr. 582: 211-216, 1992.
10. Eriksson, T., Riesbeck, K., Ostraat, O., et al. Drug exposure and flow cytometry analyses in a thalidomide schedule that prolongs rat cardiac graft survival. Trans. Proc. 24: 2560-2561, 1992.
11. Krenn, M., Gamcsik, M. P., Vogelsang, G. B., et al. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin. J. Pharm. Sci. 81: 685-689, 1992.
12. Neubert, R., Nogueira, A. C., and Neubert, D. Thalidomide and the immune system. Changes in receptors on blood cells of a healthy volunteer. Life Sci. 51: 2107-2116, 1992.
13. Lilly, C. M., Sandhu, J. S., Ishizaka, A., et al. Pentoxifylline prevents tumor necrosis factor-induced lung injury. Am. Rev. Respir. Dis. 139: 1361-1368, 1989.
14. Noel, P., Nelson, S., Bokulic, R., et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 47: 1023-1029, 1990.
15. Schade, U. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171-181, 1990.
16. Sampaio, E. P., Sarno, E. N., Galilly, R., et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. 173: 699-703, 1991.
17. Mercier. New treatments for sepsis. Critical Care Medicine 21: S310-314, 1993.
18. Neuner, P., Klosner, G., Schauer, E., et al. Pentoxyfylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology 83: 262-267, 1994.
19. Jewett, A., and Bonavida, B. Pentoxyfylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion. J. Clin. Immun. 14: 31-38, 1994.
20. Hinshaw, L., Peduzzi, P., and Young, E. Effects of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. New Engl. J. Med. 317: 659-665, 1987.